Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > BUSINESS
BUSINESS
- Sumitomo Eyes Return to Core Operating Profit in FY2024, Pruning Roivant Shares
November 1, 2023
- Otsuka Calls Off PIII Bipolar Trial for SEP-4199 on Stalled Recruitment
November 1, 2023
- Daiichi Sankyo’s H1 Sales Jump 19.5% on Robust Global Products
November 1, 2023
- Idorsia Files Insomnia Med Daridorexant in Japan: Sosei, Mochida
November 1, 2023
- Shionogi Notches Record Earnings in April-September, Xocova Drives Growth
November 1, 2023
- 301 Employees Apply for Shionogi’s Voluntary Buyout Program
November 1, 2023
- VLP Therapeutics Eyes Japan Filing of Next-Gen mRNA Vaccine in Mid-2024: CEO
October 31, 2023
- BIKEN Files Updated Version of Measles-Rubella Vaccine Mearubik
October 31, 2023
- Hyftor Now Available in EU, UK: Nobelpharma
October 31, 2023
- Nippon Kayaku Gets Japan Commercial Rights to Anheart’s ROS1 Inhibitor
October 31, 2023
- Otsuka’s ADHD Med Hits Mark in PIII Pediatric Trials in US
October 30, 2023
- Sumitomo Awards AlphaNavi Worldwide Rights to Neuropathic Pain Therapy
October 27, 2023
- Takeda’s H1 Profit Tumbles on Write-Down Tied to Trial Setbacks, Outlook Slashed
October 27, 2023
- Merck Sues Sawai over Januvia Generics Approved in Japan
October 27, 2023
- Novartis Expects Limited Impact of siRNA Therapy in Drug Cost: Exec
October 26, 2023
- Yoshindo Recalls Some Nizatidine Products over Carcinogen Risks
October 26, 2023
- Japan Approves Spikevax for Primary Shots in Six Months and Above
October 26, 2023
- BMS Files Repotrectinib in Japan for ROS1-Positive NSCLC
October 26, 2023
- With Wholesalers Narrowed Down, Hospitals Face Squeezed Discounts for GSK Products
October 25, 2023
- Yakult to Divest Cancer Portfolio to Takata, Pull Plug on New Development
October 25, 2023
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…